<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02237989</url>
  </required_header>
  <id_info>
    <org_study_id>FY2001</org_study_id>
    <nct_id>NCT02237989</nct_id>
  </id_info>
  <brief_title>Effects Of Native Collagen Type 2 Treatment</brief_title>
  <official_title>Effects Of Native Collagen Type 2 Treatment In Knee Osteoarthritis : A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eskisehir Osmangazi University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eskisehir Osmangazi University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to evaluate symptomatic efficacy of native collagen type 2 on joint&#xD;
      pain and function and its effects on urinary biological markers related to cartilage&#xD;
      degeneration in patients with knee osteoarthritis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      39 patients diagnosed with knee osteoarthritis were separated into two groups. The 1st group&#xD;
      includes 19 patients given 1500mg/day paracetamol, the 2nd group consists of 20 patients&#xD;
      given 1500mg/day paracetamol and 10mg/day native collagen type 2 for three&#xD;
      months.Pretreatment and posttreatment Visual Analog Scale, Western Ontario and McMaster&#xD;
      Universities Osteoarthritis Index (WOMAC), 20-m walking time and Short Form-36 (SF-36),&#xD;
      Coll2-1, Coll2-1NO2 and Fibulin-3 levels in urine were compared.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the Change From Baseline in Pain During Walking Visual Analog Scale (VAS Walking)</measure>
    <time_frame>3 months</time_frame>
    <description>Post treatment comparison of VAS walking between the groups minimum score is 0, maximum score is 10. The clinic of the patient worses when the score increases.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total Score</measure>
    <time_frame>3 months</time_frame>
    <description>Post treatment comparison of WOMAC between the groups minimum score is 0, maximum score is 100. The clinic of the patient worses when the score increases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Change From Baseline in 20 Meters Walking Time</measure>
    <time_frame>3 months</time_frame>
    <description>Post treatment comparison of 20 meters walking time between the groups When the time increases, clinical of the patient worses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Change From Baseline in Short Form 36 / Bodily Pain Subgroup</measure>
    <time_frame>3 months</time_frame>
    <description>Post treatment comparison of short form 36-bodily pain between groups minimum score 0 maximum score 100 When the score increases, clinic of patient gets better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Change From Baseline in Coll2-1 Levels</measure>
    <time_frame>3 months</time_frame>
    <description>Post treatment comparison of Coll2-1 levels between groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>paracetamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The 1st group includes 19 patients given 1500mg/day paracetamol for three months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>native collagen type 2 + paracetamol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The 2nd group consists of 20 patients given 1500mg/day paracetamol and 10mg/day native collagen type 2 for three months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paracetamol</intervention_name>
    <description>1500 mg</description>
    <arm_group_label>paracetamol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paracetamol+native collagen type 2</intervention_name>
    <description>paracetamol (1500 mg) + native collagen type 2 (10mg)</description>
    <arm_group_label>native collagen type 2 + paracetamol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Patients aged 45-70 years with the diagnosis of primary knee OA&#xD;
        according to the American College of Rheumatology (ACR) criteria, Kellgren Lawrence&#xD;
        radiological stage II or III and knee pain -&#xD;
&#xD;
        Exclusion Criteria:Patients with intraarticular injections or physical therapy within the&#xD;
        last year, a previous lower extremity surgery, oral treatment with glucosamine chondroitin&#xD;
        or other natural health products within the last month, serious concomitant systemic&#xD;
        diseases, peripheral or central neurological disorder, hypersensitivity to paracetamol or&#xD;
        se¬vere cardiac, renal, hepatic, hematologic disease&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fulya Bakilan, Specialist</last_name>
    <role>Study Director</role>
    <affiliation>Yerkoy State Hospital</affiliation>
  </overall_official>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 10, 2014</study_first_submitted>
  <study_first_submitted_qc>September 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2014</study_first_posted>
  <results_first_submitted>August 13, 2020</results_first_submitted>
  <results_first_submitted_qc>September 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 18, 2020</results_first_posted>
  <last_update_submitted>September 17, 2020</last_update_submitted>
  <last_update_submitted_qc>September 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Eskisehir Osmangazi University</investigator_affiliation>
    <investigator_full_name>Onur Armağan</investigator_full_name>
    <investigator_title>Onur Armagan, Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>knee osteoarthritis, native collagen type 2, paracetamol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Paracetamol</title>
          <description>The 1st group includes 19 patients given 1500mg/day paracetamol for three months&#xD;
paracetamol: 1500 mg</description>
        </group>
        <group group_id="P2">
          <title>Native Collagen Type 2 + Paracetamol</title>
          <description>The 2nd group consists of 20 patients given 1500mg/day paracetamol and 10mg/day native collagen type 2 for three months&#xD;
paracetamol+native collagen type 2: paracetamol (1500 mg) + native collagen type 2 (10mg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Paracetamol</title>
          <description>The 1st group includes 19 patients given 1500mg/day paracetamol for three months&#xD;
paracetamol: 1500 mg</description>
        </group>
        <group group_id="B2">
          <title>Native Collagen Type 2 + Paracetamol</title>
          <description>The 2nd group consists of 20 patients given 1500mg/day paracetamol and 10mg/day native collagen type 2 for three months&#xD;
paracetamol+native collagen type 2: paracetamol (1500 mg) + native collagen type 2 (10mg)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.84" spread="6.55"/>
                    <measurement group_id="B2" value="57.65" spread="8.73"/>
                    <measurement group_id="B3" value="58.2" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>the Change From Baseline in Pain During Walking Visual Analog Scale (VAS Walking)</title>
        <description>Post treatment comparison of VAS walking between the groups minimum score is 0, maximum score is 10. The clinic of the patient worses when the score increases.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paracetamol</title>
            <description>The 1st group includes 19 patients given 1500mg/day paracetamol for three months&#xD;
paracetamol: 1500 mg</description>
          </group>
          <group group_id="O2">
            <title>Native Collagen Type 2 + Paracetamol</title>
            <description>The 2nd group consists of 20 patients given 1500mg/day paracetamol and 10mg/day native collagen type 2 for three months&#xD;
paracetamol+native collagen type 2: paracetamol (1500 mg) + native collagen type 2 (10mg)</description>
          </group>
        </group_list>
        <measure>
          <title>the Change From Baseline in Pain During Walking Visual Analog Scale (VAS Walking)</title>
          <description>Post treatment comparison of VAS walking between the groups minimum score is 0, maximum score is 10. The clinic of the patient worses when the score increases.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="3" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total Score</title>
        <description>Post treatment comparison of WOMAC between the groups minimum score is 0, maximum score is 100. The clinic of the patient worses when the score increases.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paracetamol</title>
            <description>The 1st group includes 19 patients given 1500mg/day paracetamol for three months&#xD;
paracetamol: 1500 mg</description>
          </group>
          <group group_id="O2">
            <title>Native Collagen Type 2 + Paracetamol</title>
            <description>The 2nd group consists of 20 patients given 1500mg/day paracetamol and 10mg/day native collagen type 2 for three months&#xD;
paracetamol+native collagen type 2: paracetamol (1500 mg) + native collagen type 2 (10mg)</description>
          </group>
        </group_list>
        <measure>
          <title>the Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total Score</title>
          <description>Post treatment comparison of WOMAC between the groups minimum score is 0, maximum score is 100. The clinic of the patient worses when the score increases.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" lower_limit="24" upper_limit="100"/>
                    <measurement group_id="O2" value="44" lower_limit="24" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Change From Baseline in 20 Meters Walking Time</title>
        <description>Post treatment comparison of 20 meters walking time between the groups When the time increases, clinical of the patient worses</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paracetamol</title>
            <description>The 1st group includes 19 patients given 1500mg/day paracetamol for three months&#xD;
paracetamol: 1500 mg</description>
          </group>
          <group group_id="O2">
            <title>Native Collagen Type 2 + Paracetamol</title>
            <description>The 2nd group consists of 20 patients given 1500mg/day paracetamol and 10mg/day native collagen type 2 for three months&#xD;
paracetamol+native collagen type 2: paracetamol (1500 mg) + native collagen type 2 (10mg)</description>
          </group>
        </group_list>
        <measure>
          <title>the Change From Baseline in 20 Meters Walking Time</title>
          <description>Post treatment comparison of 20 meters walking time between the groups When the time increases, clinical of the patient worses</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.84" spread="4.79"/>
                    <measurement group_id="O2" value="18" spread="3.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Change From Baseline in Short Form 36 / Bodily Pain Subgroup</title>
        <description>Post treatment comparison of short form 36-bodily pain between groups minimum score 0 maximum score 100 When the score increases, clinic of patient gets better</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paracetamol</title>
            <description>The 1st group includes 19 patients given 1500mg/day paracetamol for three months&#xD;
paracetamol: 1500 mg</description>
          </group>
          <group group_id="O2">
            <title>Native Collagen Type 2 + Paracetamol</title>
            <description>The 2nd group consists of 20 patients given 1500mg/day paracetamol and 10mg/day native collagen type 2 for three months&#xD;
paracetamol+native collagen type 2: paracetamol (1500 mg) + native collagen type 2 (10mg)</description>
          </group>
        </group_list>
        <measure>
          <title>the Change From Baseline in Short Form 36 / Bodily Pain Subgroup</title>
          <description>Post treatment comparison of short form 36-bodily pain between groups minimum score 0 maximum score 100 When the score increases, clinic of patient gets better</description>
          <units>score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" lower_limit="10" upper_limit="100"/>
                    <measurement group_id="O2" value="52" lower_limit="10" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Change From Baseline in Coll2-1 Levels</title>
        <description>Post treatment comparison of Coll2-1 levels between groups</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paracetamol</title>
            <description>The 1st group includes 19 patients given 1500mg/day paracetamol for three months&#xD;
paracetamol: 1500 mg</description>
          </group>
          <group group_id="O2">
            <title>Native Collagen Type 2 + Paracetamol</title>
            <description>The 2nd group consists of 20 patients given 1500mg/day paracetamol and 10mg/day native collagen type 2 for three months&#xD;
paracetamol+native collagen type 2: paracetamol (1500 mg) + native collagen type 2 (10mg)</description>
          </group>
        </group_list>
        <measure>
          <title>the Change From Baseline in Coll2-1 Levels</title>
          <description>Post treatment comparison of Coll2-1 levels between groups</description>
          <units>microgram/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130" lower_limit="22.4" upper_limit="596.13"/>
                    <measurement group_id="O2" value="155.25" lower_limit="26.84" upper_limit="558.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment Group</title>
          <description>1500 mg/day acetaminophen and 10 mg/day of native type II collagen</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>1500 mg/day acetaminophen</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Fulya Bakılan</name_or_title>
      <organization>Eskisehir Osmangazi University</organization>
      <phone>+905057737335</phone>
      <email>fulyabakilan@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

